VS-7375: Potential Best-in-Class KRAS G12D (ON/OFF) Inhibitor FORWARD-LOOKING STATEMENTS R&D Update Call J u n e 2 3 , 2 0 2 6 Disclaimers This presentation includes forward-looking statements about, among other things, Verastem Oncology's (the "Company") programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirst ...